Catalent, Inc. (CTLT) Shares Sold by Janus Henderson Group PLC
Janus Henderson Group PLC decreased its stake in Catalent, Inc. (NYSE:CTLT) by 5.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,460,877 shares of the company’s stock after selling 366,168 shares during the quarter. Janus Henderson Group PLC owned approximately 4.86% of Catalent worth $257,918,000 at the end of the most recent quarter.
Other hedge funds also recently added to or reduced their stakes in the company. Acrospire Investment Management LLC lifted its position in Catalent by 72.2% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock worth $109,000 after buying an additional 1,300 shares in the last quarter. Quantbot Technologies LP lifted its position in Catalent by 110.7% in the 2nd quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock worth $120,000 after buying an additional 1,804 shares in the last quarter. Fortaleza Asset Management Inc. purchased a new stake in Catalent in the 3rd quarter worth approximately $164,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Catalent by 12.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock valued at $177,000 after purchasing an additional 559 shares in the last quarter. Finally, Advisor Group Inc. raised its holdings in shares of Catalent by 1.3% during the 2nd quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock valued at $180,000 after purchasing an additional 65 shares in the last quarter. Institutional investors own 99.49% of the company’s stock.
In other news, Director Uwe Roehrhoff bought 7,500 shares of the stock in a transaction that occurred on Tuesday, November 21st. The shares were acquired at an average cost of $39.22 per share, for a total transaction of $294,150.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 1.70% of the company’s stock.
Catalent, Inc. (CTLT) opened at $39.72 on Friday. Catalent, Inc. has a twelve month low of $24.30 and a twelve month high of $43.39. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.49 and a current ratio of 2.91. The firm has a market cap of $5,277.16, a price-to-earnings ratio of 27.78, a PEG ratio of 2.55 and a beta of 1.41.
Catalent (NYSE:CTLT) last posted its earnings results on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.01. Catalent had a net margin of 5.01% and a return on equity of 23.97%. The business had revenue of $543.90 million for the quarter, compared to analyst estimates of $490.75 million. During the same period last year, the business posted $0.16 EPS. Catalent’s revenue was up 23.0% compared to the same quarter last year. sell-side analysts forecast that Catalent, Inc. will post 1.46 earnings per share for the current fiscal year.
A number of research analysts have recently weighed in on the stock. Needham & Company LLC assumed coverage on shares of Catalent in a report on Tuesday, September 12th. They set a “hold” rating and a $42.00 price target on the stock. BidaskClub downgraded shares of Catalent from a “buy” rating to a “hold” rating in a report on Friday, September 15th. Bank of America restated a “buy” rating and set a $40.00 price target (up previously from $38.00) on shares of Catalent in a report on Tuesday, August 29th. Piper Jaffray Companies restated a “buy” rating and set a $45.00 price target on shares of Catalent in a report on Tuesday, August 29th. Finally, Zacks Investment Research downgraded shares of Catalent from a “buy” rating to a “hold” rating in a report on Friday, August 18th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $44.25.
TRADEMARK VIOLATION WARNING: “Catalent, Inc. (CTLT) Shares Sold by Janus Henderson Group PLC” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://theolympiareport.com/2017/12/10/catalent-inc-ctlt-shares-sold-by-janus-henderson-group-plc.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.